- Home
- QURE
QURE
uniQure N.V.
as 01-22-2025 10:42am EST
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
| Founded: | 1998 | Country: | Netherlands |
| Employees: | N/A | City: | AMSTERDAM |
| Market Cap: | 860.8M | IPO Year: | 2007 |
| Target Price: | $33.00 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.73 - $19.18 | Next Earning Date: | 02-26-2025 |
| Revenue: | $28,587,000 | Revenue Growth: | -74.45% |
| Revenue Growth (this year): | 153.92% | Revenue Growth (next year): | -11.23% |
Stock Insider Trading Activity of uniQure N.V. (QURE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kapusta Matthew C | QURE | CEO, Managing Director | Dec 10 '24 | Sell | $15.03 | 100,000 | $1,503,000.00 | 597,915 | |
| Kapusta Matthew C | QURE | CEO, Managing Director | Dec 8 '24 | Sell | $7.63 | 3,418 | $26,079.34 | 597,915 | |
| KLEMT CHRISTIAN | QURE | Chief Financial Officer | Dec 8 '24 | Sell | $7.55 | 1,796 | $13,559.80 | 166,713 |
Latest uniQure N.V. News
QURE Breaking Stock News: Dive into QURE Ticker-Specific Updates for Smart Investing
Insider Monkey
9 days ago
Here’s Why uniQure N.V. (QURE) Is Skyrocketing
Insider Monkey
11 days ago
Is uniQure N.V. (QURE) Among the Best Growth Stocks to Buy and Hold in 2025?
MT Newswires
14 days ago
uniQure Prices $75 Million Public Offering; Shares Fall
GlobeNewswire
14 days ago
uniQure Announces Pricing of its Public Offering
MT Newswires
14 days ago
uniQure Launches Public Offering of Shares, Pre-Funded Warrants
MT Newswires
15 days ago
UniQure Files Mixed Shelf; Shares Fall After Hours
GlobeNewswire
15 days ago
uniQure Announces Proposed Public Offering
MT Newswires
15 days ago
RBC Raises Price Target on uniQure to $24 From $20, Keeps Outperform, Speculative Risk
Compare QURE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "QURE uniQure N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.